BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 30399177)

  • 1. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania.
    Nandan D; Zhang N; Yu Y; Schwartz B; Chen S; Kima PE; Reiner NE
    PLoS One; 2018; 13(11):e0206920. PubMed ID: 30399177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.
    Al-Abdely HM; Graybill JR; Loebenberg D; Melby PC
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2910-4. PubMed ID: 10582881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis.
    Varela-M RE; Ochoa R; Muskus CE; Muro A; Mollinedo F
    Parasit Vectors; 2017 Oct; 10(1):458. PubMed ID: 29017516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.
    Khadem F; Jia P; Mou Z; Feiz Barazandeh A; Liu D; Keynan Y; Uzonna JE
    J Antimicrob Chemother; 2017 Feb; 72(2):467-477. PubMed ID: 27999013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
    Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
    J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
    Jain SK; Sahu R; Walker LA; Tekwani BL
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis.
    Al-Abdely HM; Graybill JR; Bocanegra R; Najvar L; Montalbo E; Regen SL; Melby PC
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2542-8. PubMed ID: 9756753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca
    Gil Z; Martinez-Sotillo N; Pinto-Martinez A; Mejias F; Martinez JC; Galindo I; Oldfield E; Benaim G
    Parasitol Res; 2020 Feb; 119(2):649-657. PubMed ID: 31897791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.
    Vishwakarma P; Parmar N; Chandrakar P; Sharma T; Kathuria M; Agnihotri PK; Siddiqi MI; Mitra K; Kar S
    Cell Mol Life Sci; 2018 Feb; 75(3):563-588. PubMed ID: 28900667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species.
    Valadares DG; Duarte MC; Oliveira JS; Chávez-Fumagalli MA; Martins VT; Costa LE; Leite JP; Santoro MM; Régis WC; Tavares CA; Coelho EA
    Parasitol Int; 2011 Dec; 60(4):357-63. PubMed ID: 21723957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmaniasis in Turkey: Visceral and cutaneous leishmaniasis caused by Leishmania donovani in Turkey.
    Özbilgin A; Harman M; Karakuş M; Bart A; Töz S; Kurt Ö; Çavuş İ; Polat E; Gündüz C; Van Gool T; Özbel Y
    Acta Trop; 2017 Sep; 173():90-96. PubMed ID: 28587839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies.
    Kariyawasam KKGDUL; Selvapandiyan A; Siriwardana HVYD; Dube A; Karunanayake P; Senanayake SASC; Dey R; Gannavaram S; Nakhasi HL; Karunaweera ND
    Parasitology; 2018 Apr; 145(4):443-452. PubMed ID: 29113609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Efficacy of Apigenin against Cutaneous Leishmaniasis: Involvement of Reactive Oxygen Species and Autophagy as a Mechanism of Action.
    Fonseca-Silva F; Inacio JD; Canto-Cavalheiro MM; Menna-Barreto RF; Almeida-Amaral EE
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004442. PubMed ID: 26862901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity.
    Saini S; Ghosh AK; Das S; Singh R; Abhishek K; Verma S; Kumar A; Mandal A; Purkait B; Sinha KK; Das P
    Vaccine; 2018 Feb; 36(9):1190-1202. PubMed ID: 29395522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani.
    Chen M; Christensen SB; Theander TG; Kharazmi A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1339-44. PubMed ID: 8092835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.